Financial Data and Key Metrics Changes - For Q4 2024, net product sales were approximately $3.3 million, compared to $1.7 million in Q4 2023, representing a significant increase [47] - For the full year 2024, net product sales reached approximately $10.2 million, up from approximately $5.2 million in 2023, indicating strong growth [47] - The net loss for Q4 2024 was approximately $1.2 million or $0.49 per share, compared to a net loss of $2 million or $7.13 per share in Q4 2023 [47] - The net loss for the full year 2024 was approximately $5.4 million or $2.81 per share, down from a net loss of $7.8 million or $27.97 per share in 2023 [47] Business Line Data and Key Metrics Changes - The growth in revenue was driven by enhanced prescription fulfillment through the Aspen Pharmacy network and increased provider awareness [48] - The fill rates increased by 72% year over year, and patient enrollments grew by 22% [12] - The prescriber base increased by 46% year over year, totaling 2,553 prescribers [12] Market Data and Key Metrics Changes - Medicaid prescriptions increased from about 2% of the business at the beginning of 2024 to between 5% and 7% by year-end [62] - The transition to Aspen pharmacies significantly accelerated delivery times and improved insurance authorization processes [12] Company Strategy and Development Direction - The company aims to expand pharmacy partnerships, improve access, and increase provider awareness to drive broader adoption of Gimoti [66] - The strategy includes leveraging real-world data to strengthen payer discussions and reinforce Gimoti's value [66] - The company plans to maintain a disciplined approach to capital allocation to maximize returns on investments in commercialization [66] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a projected net revenue of approximately $16 million for 2025, representing a 60% increase over 2024 [51] - The company acknowledged external factors such as macroeconomic conditions and supply chain constraints but remains optimistic about executing its plans [51] Other Important Information - The company raised $14.3 million in capital through equity financings and warrant exercises, extending its cash runway into Q1 2026 [50] - The company has six listed patents related to Gimoti, extending into 2030 [13] Q&A Session Summary Question: Impact of Vanda's drug and FDA's compassionate use of Domperidone - Management noted uncertainty regarding the volume of Domperidone but recognized that its discontinuation would likely lead patients to seek alternatives like Gimoti [56][58] Question: Update on increasing Medicaid and private Medicaid pharmacy - The company reported growth in Medicaid prescriptions, which increased from about 2% to between 5% and 7% of the business due to the addition of new dispensing pharmacies [62]